2025’s biggest life sciences deals show a market in rebound
Version 2 — Full analysis
A new PharmaShots ranking, built with DealForma data, highlights just how concentrated and global life sciences dealmaking became in 2025. The list’s top three transactions were all multibillion-dollar biopharma partnerships: GSK and Jiangsu Hengrui Pharmaceuticals at about $12.5 billion, Takeda and Innovent Biologics at about $11.4 billion, and BioNTech and Bristol Myers Squibb at about $11.1 billion. In other words, the year’s biggest deals weren’t just traditional takeovers. They were complex collaborations built around pipeline access, shared development risk, and increasingly, cross-border innovation sourcing. (linkedin.com)
That fits the broader market backdrop. DealForma’s 2025 review says global healthcare and life sciences M&A rose to 585 transactions with total announced value of about $269.3 billion, nearly double 2024 levels. Biopharma therapeutics and discovery platforms were the main value driver, while diagnostics also posted a sharp jump. Nature also reported that the first half of 2025 brought the highest number of biopharma M&As since 2020, alongside a strong run of licensing deals. And the reopening was not limited to M&A: PharmaShots’ Top 20 Healthcare IPOs of 2025, also using DealForma data, described sustained investor confidence across biotech, medtech, digital health, and AI-enabled healthcare companies, with capital flowing toward next-generation therapies, advanced diagnostics, and evolving care-delivery models. Medline Industries’ $7.2 billion IPO led by a wide margin, followed by Caris Life Sciences at $494 million and Lumexa Imaging at $462.5 million, reinforcing investor preference for scaled platforms, AI-enabled solutions, and revenue-generating healthcare businesses. (dealforma.com)
The top-ranked GSK-Hengrui agreement is a good example of the year’s structure. GSK said in July 2025 that it would pay $500 million upfront across agreements to develop up to 12 medicines spanning respiratory, immunology and inflammation, and oncology. One program, a PDE3/4 inhibitor for COPD, was licensed immediately, while 11 others were set up as options after phase 1 completion. GSK said the total potential value could reach about $12 billion in milestones, on top of royalties. (gsk.com)
The other top deals followed a similar playbook. In June 2025, Bristol Myers Squibb said it would pay BioNTech $1.5 billion upfront plus $2 billion in non-contingent anniversary payments through 2028 for BNT327, with BioNTech eligible for up to $7.6 billion in milestones and a 50/50 global profit-and-loss split. Takeda’s oncology deal with Innovent included a $1.2 billion upfront payment, including a $100 million equity investment, plus milestones, royalties, and a U.S. profit split on IBI363; Takeda also secured an option on IBI3001. Those structures show how buyers are paying for clinically credible assets while still preserving optionality. (news.bms.com)
Industry commentary points in the same direction. DealForma’s large-cap licensing analysis said major companies committed more than $60 billion in upfronts, milestones, and profit-sharing across key in-licensing and co-development deals from early 2024 through mid-2025. Nature noted that Chinese biopharma companies accounted for a substantial share of big-pharma deal activity and upfront payments in 2025. Locust Walk’s year-in-review went further, saying China-based sellers accounted for roughly 47% of global licensing deal value in 2025, overtaking the U.S. by value share. Taken together, that suggests 2025 was not just a rebound year, but a geographic reset in where large pharma is sourcing innovation. (dealforma.com)
Private capital was part of the story too. PharmaShots reported that Blackstone closed Blackstone Life Sciences VI at its $6.3 billion hard cap, making it the largest vehicle in that strategy and about 40% larger than its predecessor. Blackstone said its life sciences platform had about $15 billion in assets under management as of the fourth quarter of 2025 and had committed roughly $2 billion over the prior 12 months through partnerships with companies including Merck, Teva, Alnylam, and Novartis. That matters because it shows that beyond public-market and strategic-deal momentum, there is still substantial institutional capital available for drug, medtech, and royalty-linked transactions. (pharmashots.com)
There were also signs that buyers were willing to pursue large control transactions, not just partnerships. PharmaShots noted that CVC Capital Partners proposed a voluntary tender offer to acquire all outstanding shares of Recordati and delist the company, valuing the business at about €10.9 billion, or roughly $12.6 billion, at €52 per share including dividend. CVC already held about 47% of Recordati, and the proposal had not yet been reviewed by Recordati’s corporate bodies, but the situation added another data point: 2025’s appetite extended from licensing and IPOs to potential take-private deals as well. The target is also notable because Recordati had expanded its rare-disease footprint through its 2021 acquisition of EUSA Pharma, strengthening its rare cancer portfolio. (pharmashots.com)
The IPO data adds another layer to the 2025 picture. According to PharmaShots, investors were not only backing big established names but also companies tied to AI-driven drug discovery, precision medicine, digital care, and advanced devices. Among the smaller offerings on the top-20 list were companies such as Saluda Medical, a commercial-stage neuromodulation company focused on chronic pain, and Shenzhen Edge Medical, a surgical robotics developer. That mix suggests public investors were rewarding technology-integrated healthcare models alongside classic therapeutic stories, especially in oncology and metabolic disease. (pharmashots.com)
Why it matters: Veterinary professionals won’t see a direct practice impact from these human-health deals, but the financing signals matter. Large life sciences transactions influence capital markets, partner appetite, R&D hiring, manufacturing demand, and the valuation environment that animal health companies operate in too. If strategic buyers continue favoring late-stage, de-risked assets with platform potential, veterinary startups and established animal health players may face a tougher bar for fundraising unless they can show clearer clinical differentiation, stronger data, or commercial-ready platforms. The IPO rebound points the same way: investors appeared most interested in scaled platforms, AI-enabled tools, precision medicine, and businesses with clearer commercial profiles. At the same time, more money flowing into AI-enabled discovery, biologics, diagnostics, robotics, and specialty therapeutics in human health could eventually create tools, talent migration, and partnership models that benefit veterinary medicine. That last point is an inference based on broader sector dynamics, not something the deal reports state directly. (dealforma.com)
There’s also a practical business lesson here for veterinary executives and investors: the market rewarded flexibility. The biggest 2025 deals often blended upfront cash, milestone ladders, profit splits, territory carveouts, and option-based structures, rather than simple acquisitions. At the same time, the year showed multiple financing paths can coexist: strategic licensing, public offerings, large specialist funds, and even potential take-private bids. That’s relevant for animal health companies considering licensing, co-development, regional commercialization partnerships, or alternative financing structures, especially as pet parent demand continues to support interest in specialty care, chronic disease management, diagnostics, and innovation across the veterinary sector. The article source doesn’t address veterinary medicine directly, but the deal architecture is worth watching. (gsk.com)
What to watch: The next question is whether 2025 was a one-year spike or the start of a longer cycle. Early indicators from year-end analyses suggest momentum could continue into 2026, particularly in oncology, obesity, immunology, AI-enabled healthcare, and cross-border licensing. For veterinary professionals and animal health companies, the key watchpoints are whether capital remains concentrated in de-risked assets, whether AI and platform plays keep attracting premium valuations, whether large private funds continue deploying aggressively, and whether broader life sciences deal enthusiasm spills into animal health, diagnostics, and veterinary technology. (dealforma.com)